Sixteen patients with the Acquired Immunodeficiency Syndrome (AIDS) and cytomegalovirus retinitis were treated with ganciclovir alone (9 patients) or ganciclovir and zidovudine (6 patients). The duration of effective treatment, that is the number of weeks during which there was no deterioration in visual symptoms or retinal appearance, was comparable in both groups. However, six ofthe seven patients receiving concurrent therapy had to cease treatment temporarily because of bone marrow toxicity compared with one of the nine patients treated with ganciclovir alone. It is concluded that continuous concurrent therapy with oral zidovudine and intravenous ganciclovir is not possible unless unlimited supportive therapy including blood transfusion, is available.
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Cytomegalovirus (CMV) is the commonest cause of retinitis in patients with the acquired immunodeficiency syndrome (AIDS) with a reported incidence of 6-30%.-Ganciclovir (9 [1, 3- dihydroxy-2-propoxymethyll guanine) is an acyclic nucleoside which is effective in slowing the progression of CMV retinitis in AIDS patients;`" however, this drug requires life long intravenous administration and its main toxicity is bone marrow depression. The antiviral drug zuidovudine has also been reported to produce regression of CMV retinitis by a hitherto unexplained mechanism. ' The diagnosis ofCMV retinitis was made by one of us (RM) on the basis of typical fundoscopic appearances of (1) periphlebitis (2) perivascular haemorrhages and exudates. Each patient was treated with ganciclovir at an initial dose of 7-5 mg/kg/day for 21 days, followed by maintenance therapy of 2.5 mg/kg/day. Treatment was given daily via an indwelling Hickman catheter and increased by 2-5 mg/kg/day if visual deterioration occurred. The treatment regime for zidovudine was 200 mg four hourly.
All the patients were monitored for toxicity by having weekly full blood counts and differential white cell counts, and ophthalmic examination. Changes in visual symptoms or retinal appearance were noted weekly. Treatment was considered effective for any week when visual symptoms and retinal appearances remained stable or improved.
Blood transfusions were given if the haemoglobin was below 8 gm/dl. Unacceptable bone marrow toxicity was defined as (1) more than 4 units of blood transfusion required within 14 days to maintain haemoglobin above 8 gm/dl (2) a total white cell count < 1 x 109/1. If bone marrow toxicity occurred then treatment with zidovudine (if patient on both drugs) or ganciclovir was stopped until the haemoglobin and/or white cell count had remained above these levels for 14 days (without blood transfusion).
Treatment of cytomegalovirus retinitis with zidovudine and ganciclovir in patients with AIDS: outcome and toxicity At the time of this study, the antiviral agent zidovudine had been shown to prolong survival and decrease the frequency of opportunistic infections in patients with AIDS and ARC.'7 These effects may be due to an immunomodulating effect of zidovudine, although documented changes in CD4, numbers have been transient. '7 There have been reports of regression of CMV retinitis in AIDS patients treated with this drug which has no direct anti CMV effect. '4'5 This may be comparable with the regression in CMV retinitis which occurs on reversal of transient immunodeficiency states.'8 Another explanation, as suggested by Skolnick, might be that infection with HIV and CMV increases replication of both viruses and hence inhibition of either would slow down progression of both.'9 It would seem likely in view of these findings that concurrent therapy with ganciclovir and zidovudine would be advantageous in AIDS patients with CMV retinitis, but they have rarely been given in this way because of their shared toxicity to the bone marrow. One report of such treatment found it possible to use the drugs concurrently but gave unlimited transfusion (average 2-4 units per patient) and reduced treatment on the basis ofgranulocytopenia alone.') In this study the patients were given ganciclovir 5 mg/kg/day for five or seven days per week as maintenance therapy. At the time of our study the recommended dose of maintenance therapy for ganciclovir was 2.5 mg/kg/day and despite this we had considerable tranfusion requirements, such that zidovudine treatment was withdrawn temporarily in six of the seven patients. We found no evidence of synergism in terms of duration of retinal stabilisation, but as zidovudine was stopped in so many cases synergy was not adequately assessed. Many ofour patients had abnormal haematological parameters prior to ganciclovir treatment which may have contributed to the cytopenias which developed in many, and other forms of therapy should be considered in this situation. Foscarnet is an alternative anti-CMV agent which has little haematological toxicity and may be combined with zidovudine therapy; however it may produce electrolyte disturbances and nephrotoxicity and is administered over a prolonged period.2'
We consider that the toxic effects of concurrent therapy with ganciclovir and zidovudine are unacceptable and we suggest that the use of alternative methods of drug delivery should be further explored. Intravitreal injections of ganciclovir and the newer anti CMV agent foscarnet have been reported to meet with some success.2224 Concurrent therapy with zidovudine and intravitreal anti CMV therapy might produce synergistic effects without the considerable toxicity we have encountered.
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